Serum γ-Glutamyltranspeptidase Predicts All-cause, Cardiovascular and Liver Mortality in Older Adults

Journal of Clinical and Experimental Hepatology

Volumn 3, Issue 1, 2013, Pages 4-11

  Loomba, Rohit ^a,b   Doycheva, Iliana ^a   Bettencourt, Ricki ^b   Cohen, Benjamin ^a   Wassel, Christina L ^b   Brenner, David ^a   Barrett Connor, Elizabeth ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Death; GGT; NAFLD

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ALL CAUSE MORTALITY; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIVER DISEASE; LIVER MORTALITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84875810824     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2012.10.004     Document Type: Article

References (41)

1. Whitfield J.B. Gamma glutamyltransferase. Crit Rev Clin Lab Sci 2001, 38:263-355.
2. Glass G.A., Stark A.A. Promotion of glutathione-gamma-glutamyltranspeptidase-dependent lipid peroxidation by copper and ceruloplasmin: the requirement for iron and the effects of antioxidants and antioxidant enzymes. Environ Mol Mutagen 1997, 29:73-80.
3. Ravuri C., Svineng G., Pankiv S., Huseby N.E. Endogenous production of reactive oxygen species by the NADPH oxidase complexes is a determinant of γ-glutamyltransferase expression. Free Radic Res 2011, 45:600-610.
4. Mason J.E., Starke R.D., Van Kirk J.E. Gamma-glutamyltransferase: a novel cardiovascular risk biomarker. Prev Cardiol 2010, 13:36-41.
5. Grundy S.M. Gamma-glutamyl transferase: another biomarker for metabolic syndrome and cardiovascular risk. Arterioscler Thromb Vasc Biol 2007, 27:4-7.
6. Franzini M., Corti A., Martinelli B., et al. Gamma-glutamyltransferase activity in human atherosclerotic plaques- biochemical similarities with circulating enzyme. Atherosclerosis 2009, 202:119-127.
7. Loomba R., Rao F., Zhang L., et al. Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins. Gastroenterology 2010, 139:836-845. 845. e1.
8. Lee D.H., Silventoinen K., Hu G., et al. Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. Eur Heart J 2006, 27:2170-2176.
9. Fraser A., Harris R., Sattar N., Ebrahim S., Smith G.D., Lawlor D.A. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler ThrombVasc Biol 2007, 27:2729-2735.
10. Ruttmann E., Brant L.J., Concin H., Diem G., Rapp K., Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005, 112:2130-2137.
11. Strasak A.M., Kelleher C.C., Klenk J., et al. Longitudinal change in serum gamma-glutamyltransferase and cardiovascular disease mortality: a prospective population-based study in 76,113 Austrian adults. Arterioscler Thromb Vasc Biol 2008, 28:1857-1865.
12. Lee D.S., Evans J.C., Robins S.J., et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler ThrombVasc Biol 2007, 27:127-133.
13. Ruhl C.E., Everhart J.E. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 2009, 136:477-485. e11.
14. Lee D.H., Buijsse B., Steffen L., Holtzman J., Luepker R., Jacobs D.R. Association between serum gamma-glutamyltransferase and cardiovascular mortality varies by age: the Minnesota Heart Survey. Eur J Cardiovasc Prev Rehabil 2009, 16:16-20.
15. Ghouri N., Preiss D., Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 2010, 52:1156-1161.
16. Barrett-Connor E., Khaw K. Family history of heart attack as an independent predictor of death due to cardiovascular disease. Circulation 1984, 69:1065-1069.
17. Barrett-Connor E.L., Cohn B.A., Wingard D.L., Edelstein S.L. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 1991, 265:627-631.
18. Barrett-Connor E., Wingard D.L., Criqui M.H. Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited. JAMA 1989, 261:2095-2100.
19. Loomba R., Bettencourt R., Barrett-Connor E. Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: the Rancho Bernardo Study. Aliment Pharmacol Ther 2009, 30:1137-1149.
20. The hypertension detection and follow-up program: hypertension detection and follow-up program cooperative group. Prev Med 1976, 5:207-215.
21. Lipid research clinics program manual of laboratory operations. Lipid and Lipoprotein Analysis 1974, vol. 1. US Government Printing Office, US Dept of Health, Education, and Welfare, Washington, DC, NIH Publication No. 75-628. 2nd ed.
22. Barrett-Connor E., Suarez L. A community study of alcohol and other factors associated with the distribution of high density lipoprotein cholesterol in older vs. younger men. Am J Epidemiol 1982, 115:888-893.
23. Everhart J.E., Ruhl C.E. Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas. Gastroenterology 2009, 136:1134-1144.
24. Lim J.S., Kim Y.J., Chun B.Y., Yang J.H., Lee D.H., Kam S. The association between serum GGT level within normal range and risk factors of cardiovascular diseases. J Prev Med Public Health 2005, 38:101-106.
25. Park J.S., Kang S.A., Yoo J.S., et al. Association between γ-glutamyltransferase, adiponectin and arterial stiffness. J Atheroscler Thromb 2012, 19:90-97.
26. Atar A.I., Yilmaz O.C., Akin K., Selcoki Y., Er O., Eryonucu B. Association between gamma-glutamyltransferase and coronary artery calcification. Int J Cardiol 2012, Ahead of print.
27. Emdin M., Passino C., Michelassi C., Donato L., Pompella A., Paolicchi A. Additive prognostic value of gamma-glutamyltransferase in coronary artery disease. Int J Cardiol 2009, 136:80-85.
28. Kazemi-Shirazi L., Endler G., Winkler S., Schickbauer T., Wagner O., Marsik C. Gamma glutamyltransferase and long-term survival: is it just the liver?. Clin Chem 2007, 53:940-946.
29. Monami M., Balzi D., Lamanna C., et al. Prognostic value of serum liver enzymes levels in type 2 diabetic patients. Diabetes Metab Res Rev 2007, 23:625-630.
30. Kengne A.P., Czernichow S., Stamatakis E., Hamer M., Batty G.D. Gamma-glutamyltransferase and risk of cardiovascular disease mortality in people with and without diabetes: pooling of three British Health Surveys. J Hepatol 2012, Ahead of print.
31. Sluik D., Beulens J.W., Weikert C., et al. Gamma-glutamyltrasferase, cardiovascular disease and mortality in individuals with diabetes mellitus. Diabetes Metab Res Rev 2012, 28:284-288.
32. Aksakal E., Tanboga I.H., Kurt M., et al. The relation of serum gamma-glutamyltransferase levels with coronary lesion complexity and long-term outcome in patients with stable coronary artery disease. Atherosclerosis 2012, 221:596-601.
33. Wannamethee S.G., Lennon L., Shaper A.G. The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. Atherosclerosis 2008, 201:168-175.
34. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
35. Rafiq N., Bai C., Fang Y., et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009, 7:234-238.
36. Ekstedt M., Franzén L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
37. Söderberg C., Stal P., Askling J., et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010, 51:595-602.
38. Kozakova M., Palombo C., Eng M.P., et al. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology 2012, 55:1406-1415.
39. Haring R., Wallaschofski H., Nauck M., Dörr M., Baumeister S.E., Völzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009, 50:1403-1411.
40. Emdin M., Pompella A., Paolicchi A. Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation 2005, 112:2078-2080.
41. Armstrong G.L., Wasley A., Simard E.P., McQuillan G.M., Kuhnert W.L., Alter M.J. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.